NCT01347788 Matt Smith dose finding study in mCRPC
An interesting aside to this week's trading.
As of the 5/22/13 update, this MGH-sponsored P1 trial's status has changed from "active-not recruiting" to "This study has been completed". I look forward to Dr Matt's continued support and advancement of Cabo.
Though I feel this stock will continue it's manipulated, rangebound path into the summer trading season, I remain a pullback buyer & accumulator. ASCO is but one week out, and I feel the news there will be a continuation of the positive data trend we've witnessd these past two years. Though I don't expect earth-shattering revelations next week, I do feel that Doc Scher's forward-looking oral presentation will relocate the trading range toward the higher manipulated rangebound end of that spectrum.
In other words, expect to pay a bit more for EXEL if you buy post-ASCO.
We may not be getting there fast, but we are headed in the right direction.